HHS sets AI challenges to root out causes of chronic diseasesMentari pockets another $200M for migraine ambitionsRoyalty Pharma buys part of Neurimmune's cliramitug royaltiesHHS sets AI challenges to root out causes of chronic diseasesAs part of President Donald Trump's Genesis Mission to use AI for scientific discoveries, the US Department of Health and Human Services (HHS) teamed up with the White House Office of Science and Technology Policy (OSTP) to launch a series of National Science and Technology Challenges open for the country's scientific community to solve. The White House has committed more than $5 billion in federal funding to support scientists using next-generation AI to address pressing health challenges. The primary challenge is focused on identifying the root causes of chronic disease, while additional efforts will help advance paediatric cancer research, as well as accelerate drug discovery and development by using AI to find therapeutic targets faster."By applying advanced AI tools to large and complex datasets with appropriate security and privacy protection spanning multiple scientific disciplines, researchers will be challenged to uncover previously unseen patterns, generate new hypotheses, and identify promising pathways for prevention and treatment," the HHS said in a release Wednesday.Mentari pockets another $200M for migraine ambitionsMentari Therapeutics, slated to go public soon in a reverse merger with InMed Pharmaceuticals, said Wednesday it will raise a further $200 million, on top of the $290-million private placement it announced in May alongside its merger plans. The additional funding extends Mentari's cash runway into 2029 and will support the company through Phase IIa readouts for its co-lead assets: MT-001, an anti-PACAP mAb, and MT-002, a bispecific antibody targeting CGRP and PACAP. The two assets are intended to treat both chronic and episodic migraine.The latest private placement was backed by investors including Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, BB BiotechRoyalty Pharma buys part of Neurimmune's cliramitug royaltiesRoyalty Pharma signed a deal worth up to $425 million to acquire a portion of Neurimmune’s royalty interest in cliramitug, a mAb designed to clear cardiac amyloid fibril deposits. Neurimmune had out-licensed exclusive, worldwide rights for the asset to AstraZeneca in a 2022 deal valued at $760 million.AstraZeneca is evaluating cliramitug in the Phase III DepleTTR-CM trial involving patients with transthyretin-mediated amyloid cardiomyopathy; results are expected in 2028.Under the terms of the deal, Royalty Pharma will spend $125 million upfront to receive a 3% to 4% royalty on worldwide net sales of cliramitug. Neurimmune is eligible for an additional $125 million cash payment in the first quarter of 2027, with the remaining $175 million contingent on certain clinical and regulatory milestones for the mAb.